Evolent Health issued guidance for the second quarter and reaffirmed its outlook for full year 2018.
For the second quarter, the company expects adjusted revenue of about $139.0 million to $143.0 million, and adjusted EBITDA of approximately $3.0 million to $5.0 million.
For the first quarter, Evolent Health reported a net loss attributable to the company of $13.6 million, or 18 cents per share, compared to a net loss of $18.0 million, or 34 cents per share, in the year-ago period.
For full year 2018, the company continues to expect adjusted revenue of approximately $565.0 million to $585.0 million, and adjusted EBITDA of about $18.0 million to $23.0 million.
